drugset / Trial / NCT02281422
An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Open-label, single-dose (BIA 2-093 800 mg tablet), single-centre study in five groups of subjects with various degrees of renal function based on creatinine clearance
Timeline
- Start
- 2005-03
- Primary completion
- 2006-06
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eslicarbazepine acetate | Unknown | 800 mg | — |